Complete title: A Multi-Center, Open Label Phase 1/2 Study of CYT-0851, An Oral RAD51 Inhibitor, In Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors
Research Study Number | RG1006339 |
Principal Investigator | Ryan Lynch |
Phase | I/II |
Other eligibility criteria may apply.
Research Study Number | RG1006339 |
Keywords: Breast Cancer; Multiple Myeloma (MM); Lymphoma, Non-Hodgkin (NHL); Ovarian Cancer; Pancreatic Cancer
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Please remember:
Talk to your health care providers first before making decisions about your health care.
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.